Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
TARS Shariah Compliance
Screening Methodology: AAOIFI
HALAL
Last Updated: May 12, 2026
Report Source: 2026 1st Quarter Report
Tarsus Pharmaceuticals Inc. Stock Analysis TARS
United States Health Care Mid Cap Report: Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. The company is headquartered in Irvine, California and currently employs 370 full-time employees. The company went IPO on 2020-10-16. The firm is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The firm is investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.
Read More Tarsus Pharmaceuticals Inc (TARS) Chart
Key Statistics of Tarsus Pharmaceuticals Inc (TARS)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$63.88Volume
1.29MP/E Ratio (TTM)
-52 Week Range
Market Cap
2.73BAvg. Volume
634.33KDividend Yield
-Financial Metrics & Statements of Tarsus Pharmaceuticals Inc (TARS)
FAQ's for Tarsus Pharmaceuticals Inc (TARS)
- According to Musaffa’s Shariah screening methodology, Tarsus Pharmaceuticals Inc (TARS) is currently classified as HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Tarsus Pharmaceuticals Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Tarsus Pharmaceuticals Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Tarsus Pharmaceuticals Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Tarsus Pharmaceuticals Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Tarsus Pharmaceuticals Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.